NICE appraisals are based on robust clinical evidence, cost-effectiveness analysis, and post-marketing safety data standards that investigational peptides do not yet meet
Retatrutide (also referred to as LY3437943) is an investigational triple receptor agonist that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
Other reasons to contact your provider include: Weight loss that significantly exceeds your prescribed treatment plan Cold sensations accompanied by sweating, tremor, or confusion (possible hypoglycemia, especially if taking insulin or sulfonylureas) Persistent fatigue with pallor or weakness (possible anemia) Severe or persistent symptoms that significantly impact quality of life or do not improve with conservative measures Your healthcare provider can assess whether symptoms represent expected physiological adaptation, require investigation for alternative causes (including blood tests for thyroid function, complete blood count, iron studies, or vitamin B12 levels), or indicate a need for medication adjustment
The GLP-1 and GIP components still work, maintaining appetite suppression
